



# P(O)Me<sub>2</sub>-containing Building Blocks for Drug Design

## Introduction


Phosphine oxides belong to a chemical class seldom employed in drug design. However, the FDA-approval of *Brigatinib* drug (ARIAD Pharm.) in 2017 may further inspire application of this unique functional group in medicinal chemistry. The highly ionic P=O bond imparts a number of important drug-like properties, including decreased lipophilicity, increased aqueous solubility, H-bond acceptor ability, and high metabolic stability.<sup>1-3</sup> Herein we have designed and synthesized a library of phosphine oxide derivatives for drug design.



## Discovery of *Brigatinib*



We offer >30 unique P(O)Me<sub>2</sub>-containing derivatives on a 5-50 g scale from our stock.



## References

1. W.-S. Huang et al. *J. Med. Chem.* **2016**, *59*, 4948.
2. A. A. Kamel. *International Journal of Chemical and Biomedical Science*, **2015**, *1*, 56.
3. V. Iaroshenko. *Organophosphorus Chemistry: From Molecules to Applications*, John Wiley & Sons, **2019**, 568.